Research Study

A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Intravenous NA-1 in Subjects With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy
Principal Investigator 
Thalia Field

Overview

Body Locations and Systems 
Stroke
Diagnosis and Therapy 
Stroke Rehabilitation
ClinicalTrials.gov# 
NCT02930018
Status 
Recruiting
Study Start/End 
Jul 25, 2017 to Dec 31, 2020
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Genoveva Maclean / Study Coordinator
Phone 
604-875-4111 Ext: 62100
Purpose of Study 

The ESCAPE-NA-1 study is designed to determine the safety and efficacy of the neuroprotectant, NA-1, in reducing global disability in subjects with major acute ischemic stroke (AIS) who are selected for endovascular revascularization.

Eligibility 

SeeClinicaltrials.gov

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.